Affiliation: University of Munich
- Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS)Corinna Trebst
Department of Neurology, Hannover Medical School, Hannover, Germany
J Neurol 261:1-16. 2014..Promising new therapies are emerging in the form of anti-IL6 receptor, anti-complement or anti-AQP4-Ab biologicals. ..
- Familial Mediterranean fever-associated mutation pyrin E148Q as a potential risk factor for multiple sclerosisT Kümpfel
Institute of Clinical Neuroimmunology Großhadern, Ludwig Maximilians University of Munich, Germany
Mult Scler 18:1229-38. 2012..A possible association of FMF and multiple sclerosis (MS) has been suggested in cohorts from Turkey and Israel...
- Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patientsSven Jarius
Neurocure, Charite University Medicine Berlin, Berlin, Germany
J Neuroinflammation 9:14. 2012..However, little is known so far about the clinical impact of AQP4-Ab seropositivity...
- Rebound of disease activity after withdrawal of fingolimod (FTY720) treatmentJoachim B Havla
Institute of Clinical Neuroimmunology, Ludwig Maximilians University, Marchioninistr 15, 81377 Munich, Germany
Arch Neurol 69:262-4. 2012..To date, data about a possible recurrence of disease activity after discontinuation of fingolimod treatment are scarce...
- Monthly intravenous methylprednisolone in relapsing-remitting multiple sclerosis - reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrationsFlorian Then Bergh
Section of Neurology, Max Planck Institut fur Psychiatrie, Munchen, Germany
BMC Neurol 6:19. 2006..Intermittent IV-MP, alone or with immunomodulators, has been suggested but insufficiently studied as a strategy to prevent relapses...
- Multiple sclerosis. TNFRSF1A, TRAPS and multiple sclerosisTania Kümpfel
Institute of Clinical Neuroimmunology Campus Grosshadern, Ludwig Maximilians University of Munich, Marchioninistrasse 15, Munich, Germany
Nat Rev Neurol 5:528-9. 2009..This locus is of special interest because the R92Q substitution was previously detected in a group of multiple sclerosis patients who had additional symptoms compatible with the autoinflammatory syndrome TRAPS...
- Multiple sclerosis and the TNFRSF1A R92Q mutation: clinical characteristics of 21 casesT Kümpfel
Institute of Clinical Neuroimmunology Grosshadern, Ludwig Maximilians University of Munich, Munich, Germany
Neurology 71:1812-20. 2008..The current study presents the characteristics of a larger cohort of MS patients carrying this mutation...
- Time of interferon-beta 1a injection and duration of treatment affect clinical side effects and acute changes of plasma hormone and cytokine levels in multiple sclerosis patientsT Kümpfel
Institute of Clinical Neuroimmunology, Klinikum Grosshadern, Ludwig Maximilians Universitat, Munich, Germany
Mult Scler 13:1138-45. 2007..This may have implications on the tolerability and effectiveness of IFN-beta therapy...
- Late-onset tumor necrosis factor receptor-associated periodic syndrome in multiple sclerosis patients carrying the TNFRSF1A R92Q mutationTania Kümpfel
Institute of Clinical Neuroimmunology Grosshadern, Ludwig Maximilian University of Munich, Marchioninistrasse 15, D 81377 Munich, Germany
Arthritis Rheum 56:2774-83. 2007..We undertook this study to investigate the prevalence of TRAPS in patients with multiple sclerosis (MS) who reported, in addition to their neurologic symptoms, at least 2 other symptoms compatible with TRAPS...
- De-escalation from natalizumab in multiple sclerosis: recurrence of disease activity despite switching to glatiramer acetateJoachim Havla
Institute of Clinical Neuroimmunology, Medical Campus Grosshadern, Ludwig Maximilians University, Marchioninistr 15, 81377 Munich, Germany
J Neurol 258:1665-9. 2011..Further treatment strategies are warranted for patients who discontinue NAT therapy...
- Delayed allergic reaction to natalizumab associated with early formation of neutralizing antibodiesMarkus Krumbholz
Institute for Clinical Neuroimmunology, Ludwig Maximilian University, Marchioninistrasse 15, 81377 Munich, Germany
Arch Neurol 64:1331-3. 2007..In the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) trial, infusion-related hypersensitivity reactions developed in 4% of patients, usually within 2 hours after starting the infusion...
- Favorable response to rituximab in a patient with anti-VGCC-positive Lambert-Eaton myasthenic syndrome and cerebellar dysfunctionHannah L Pellkofer
Institute of Clinical Neuroimmunology, Ludwig Maximilians University, Campus Grosshadern, Marchioninistr 15, D 81377 Munich, Germany
Muscle Nerve 40:305-8. 2009..While conventional immunosuppressive therapy (steroids, azathioprine) failed, he improved with plasma exchange and consecutive treatment with rituximab. Muscle Nerve 40: 305-308, 2009...
- Anti-CD20 B-cell depletion enhances monocyte reactivity in neuroimmunological disordersKlaus Lehmann-Horn
Department of Neurology, Technische Universitat Munchen, Munich, Germany
J Neuroinflammation 8:146. 2011..We elucidated the regulatory role of un-activated B-cells in EAE and investigated whether anti-CD20 may collaterally diminish regulatory B-cell properties in treatment of neuroimmunological disorders...
- Matching of oligoclonal immunoglobulin transcriptomes and proteomes of cerebrospinal fluid in multiple sclerosisBirgit Obermeier
Institute of Clinical Neuroimmunology, Ludwig Maximilians University, University Hospital Grosshadern, Marchioninistrasse 15, D 81377 Munich, Germany
Nat Med 14:688-93. 2008..This approach can be applied to other organ-specific diagnostic fluid or tissue samples to compare the Ig transcripts of local B cells with the corresponding antibody proteomes of individual subjects...
- Quantification of perfusion and permeability in multiple sclerosis: dynamic contrast-enhanced MRI in 3D at 3TMichael Ingrisch
Josef Lissner Laboratory for Biomedical Imaging, Department of Clinical Radiology, University Hospitals Munich Grosshadern, Ludwig Maximilian University of Munich, Germany
Invest Radiol 47:252-8. 2012....
- Fatigue and regulation of the hypothalamo-pituitary-adrenal axis in multiple sclerosisMichaela Gottschalk
Max Planck Institute of Psychiatry, Munich, Germany
Arch Neurol 62:277-80. 2005..Fatigue is a common and disabling symptom in patients with multiple sclerosis (MS). Underlying mechanisms postulated so far have involved localization of brain lesions and abnormalities of the neuroendocrine system and cytokine regulation...
- Activity of the hypothalamic-pituitary-adrenal axis in multiple sclerosis: correlations with gadolinium-enhancing lesions and ventricular volumeErina M Schumann
Max Planck Institute of Psychiatry, Munich, Germany
Ann Neurol 51:763-7. 2002..In contrast, the nature of the correlation between hypothalamic-pituitary-adrenal hyperdrive and brain atrophy remains to be determined...